Akebia doses first patient in Phase 2 ebribafusp trial for rare complement-mediated kidney diseases
AKBA•Program scope
Up to 30 patients are planned, positioning the program for a clearer go/no-go decision on broader development.
AKBA•AKBA•AKBA•Up to 30 patients are planned, positioning the program for a clearer go/no-go decision on broader development.
The study aims to show whether the drug can reduce kidney inflammation and protein leakage while maintaining broader immune defenses. Initial results have not been presented; first data are expected in 2027.
Akebia Therapeutics dosed the first patient in an open-label Phase 2 basket trial of ebribafusp for rare kidney diseases.
